These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17350261)

  • 1. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
    Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
    Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
    Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
    J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N; Patel DS; Bharatam PV
    J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
    Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
    Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
    Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
    Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
    O'Neill DJ; Shen L; Prouty C; Conway BR; Westover L; Xu JZ; Zhang HC; Maryanoff BE; Murray WV; Demarest KT; Kuo GH
    Bioorg Med Chem; 2004 Jun; 12(12):3167-85. PubMed ID: 15158785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
    Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
    Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
    Akhtar M; Bharatam PV
    Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
    Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
    Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.
    Maeda Y; Nakano M; Sato H; Miyazaki Y; Schweiker SL; Smith JL; Truesdale AT
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3907-11. PubMed ID: 15225695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M; Patel R; Khan T; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Biological Evaluation of 7-Chloro-9
    Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
    Ye Q; Mao W; Zhou Y; Xu L; Li Q; Gao Y; Wang J; Li C; Xu Y; Xu Y; Liao H; Zhang L; Gao J; Li J; Pang T
    Bioorg Med Chem; 2015 Mar; 23(5):1179-88. PubMed ID: 25662701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β.
    Atilla-Gokcumen GE; Di Costanzo L; Meggers E
    J Biol Inorg Chem; 2011 Jan; 16(1):45-50. PubMed ID: 20821241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent and bioavailable GSK-3beta inhibitors.
    Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
    Furlotti G; Alisi MA; Cazzolla N; Dragone P; Durando L; Magarò G; Mancini F; Mangano G; Ombrato R; Vitiello M; Armirotti A; Capurro V; Lanfranco M; Ottonello G; Summa M; Reggiani A
    J Med Chem; 2015 Nov; 58(22):8920-37. PubMed ID: 26486317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.
    Shen L; Prouty C; Conway BR; Westover L; Xu JZ; Look RA; Chen X; Beavers MP; Roberts J; Murray WV; Demarest KT; Kuo GH
    Bioorg Med Chem; 2004 Mar; 12(5):1239-55. PubMed ID: 14980636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.